MaxWell Biosystems
Provides next generation high-content electrophysiology platforms to facilitate detailed investigation of cells in vitro.
| EUR | 2016 | 2017 | 2018 |
|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 |
| % growth | - | (8 %) | 4 % |
| EBITDA | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
MaxWell Biosystems AG is a pioneering company in the field of neuroscience research and preclinical drug discovery. The company specializes in developing high-resolution microelectrode array (MEA) technology, which is crucial for studying neuronal networks both in 2D and 3D environments. Their flagship products, MaxOne and MaxTwo, are CMOS-based high-density MEA systems. CMOS technology allows for compact yet powerful integration of amplifiers, filters, and digitizers, making these systems highly efficient and effective for detailed cellular analysis.
MaxWell Biosystems serves a diverse range of clients, including academic researchers, pharmaceutical companies, and biotech firms. These clients are primarily engaged in basic neuroscience research, drug discovery, safety pharmacology, and toxicology. The company's technology is particularly valuable for long-term monitoring of single-cell activity and the dynamics of entire neuronal networks, providing critical insights that can accelerate the development of new drugs and therapies.
Operating in the biotechnology and life sciences market, MaxWell Biosystems employs a business model centered around the sale of its high-tech MEA systems and accompanying software modules, such as MaxLab Live. These products enable clients to conduct comprehensive data analysis, selective electrical stimulation, and label-free detection of sub-cellular and network activity. The company also generates revenue through service contracts, maintenance, and customer support, ensuring that clients can maximize the utility of their MEA systems.
In summary, MaxWell Biosystems AG is at the forefront of advancing neuroscience research and drug discovery through its innovative high-resolution MEA technology. By providing cutting-edge tools and comprehensive support, the company helps its clients achieve breakthroughs in understanding neuronal behavior and developing new medical treatments.
Keywords: neuroscience, drug discovery, MEA technology, CMOS, high-density, neuronal networks, pharmaceutical, biotech, data analysis, preclinical research.